KEY FINDINGS The Latin America market for the CGMA is estimated to grow $ 798.58 million by 2025 at CAGR of 47.84%. The forecast period of the CGMA market is from 2017 to 2025 and the base year deliberated for the market study is 2016. With an awareness of benefits of using continuous glucose monitoring systems, better healthcare infrastructure, accelerated incidences of diabetes due to a sedentary lifestyle and high healthcare expenditure, increase in the number of people suffering from diabetes, authorization of artificial pancreas, greater awareness, and improved healthcare infrastructure and ease of using CGMS devices are some of the factors leading to the market growth.
MARKET INSIGHTS The market is segmented by application, product type, and geography. There are diverse product types comprising CGMS including the transmitters and receivers, and the sensors. The Sensors are further segmented on the basis of holter type retrospective sensors, insulin pumps, non-invasive glucose sensors, minimally invasive glucose sensors and real-time sensors. The glucose monitors applications end-users include homes, hospitals, diagnostics and clinics.
Hospitals have the largest market share in terms of the end-user segment. The highest CAGR is expected for Home healthcare as an end-user. High costing of continuous glucose monitoring systems, deficient reimbursement options, and stringent regulatory norms are the factors that are likely to restrain the market growth.
High acceleration in the prevalence of diabetes, rising health awareness in developing countries, changes in lifestyle, sedentary lifestyle, the rise in the need of efficient and hassle-free monitoring of blood and the launch of an artificial pancreas are the market drivers for CGMS.
COMPETITIVE INSIGHTS The major companies that are mentioned in CGMA market report are Medtronic Inc., Ypsomed AG, Novo Nordisk, Bayer AG Roche, Animas Corporation, Glysens Inc., Abbott Laboratories, Insulet Corporation, and Dexcom Inc.
Our reports have been used by over 10K customers, including:
KEY FINDINGS The Latin America Continuous Glucose Monitoring System (CGMS) market stood at $47.6 million in 2017 and is expected to reach $865.3 million by 2026, exhibiting a CAGR of 37.94% over the forecast period of 2018-2026. Also, the Latin America Self-Monitoring of Blood Glucose (SMBG) market is expected to...
Mexico Diabetes Care Devices Market Outlook to 2022 - Glucose Monitoring and Insulin Delivery Summary GlobalData’s new report, "Mexico Diabetes Care Devices Market Outlook to 2022", provides key market data on the Mexico Diabetes Care Devices market. The report provides value, in millions of US dollars and volume (in units)...